Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kymera Therapeutics, Inc.

https://www.kymeratx.com/

Latest From Kymera Therapeutics, Inc.

Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera

Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.

Companies Research & Development

Rough Guide To Targeted Protein Degradation

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

Companies Research & Development

Scrip’s Rough Guide To Targeted Protein Degradation

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

Companies Research & Development

Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs

Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings. 

Financing Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Kymera Therapeutics, LLC.
UsernamePublicRestriction

Register